Stage IV Cutaneous Melanoma AJCC v6 and v7 Suspended Phase 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0091050 (Stage IV Cutaneous Melanoma AJCC v6 and v7)Suspended2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03050060Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTreatment